Cat. No.: HY-N3021

D-chiro-Inositol

Customer Review

Based on 1 Customer Validation

D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 643-12-9
Formula: C₆H₁₂O₆
Molecular Weight:180.16

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

D-chiro-Inositol Chemical Structure

CAS No.: 643-12-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

All NF-κB Isoforms :

All TNF Receptor Isoforms :

All FOXO Isoforms :

FOXO1
FOXO3

In Vitro

D-chiro-Inositol (0.1-10 μmol, 3 h) improves glucose metabolism in HepG2 cells treated with Palmitoleic acid (HY-W011873) and inhibited the activity of FOXO1^[3].
D-chiro-Inositol (1-40 mM, 48 h) inhibites the growth of breast cancer cells MDA-MB-231^[4].
D-chiro-Inositol (0.125-1 mM, 24 and 48 h) regulates the GSH/GSSG ratio of 3T3-L1 adipocytes and reduces the pro-inflammatory state of cells^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[3]

Cell Line:

PA-treated HepG2 cells
Concentration:

0.1-10 μmol
Incubation Time:

3 h
Result:

Increased the mRNA expression levels of PEPCK and G6 Pase in HepG2 cells.

Western Blot Analysis^[3]

Cell Line:

PA-treated HepG2 cells
Concentration:

0.1-10 μmol
Incubation Time:

3 h
Result:

Inhibited the downregulation of IR β and p85 subunit expression levels and restored the phosphorylation levels of IRS-2, AKT and FOXO1.

Cell Proliferation Assay^[4]

Cell Line:

MDA-MB-231 cells
Concentration:

1, 5, 10, 20 and 40 mM
Incubation Time:

48 h
Result:

The cell proliferation abilities decreased by 18.3%, 17.2%, 17.5%, 18.4% and 24.9%, respectively.

In Vivo

D-chiro-Inositol (150 mg/kg; p.o.; once daily for 2 weeks) reduces hepatic bile acid accumulation and reduces the severity of liver damage and fibrosis in rats with cholestasis model^[2].
D-chiro-Inositol (50 mg/kg; i,g.; once daily for 8 weeks) enhances glucose tolerance and reduces lipid accumulation in the liver in mice fed a high-fat diet^[3].
D-chiro-Inositol (500 and 1000 mg/kg; p.o.; once daily for 45 days) inhibits tumor growth in a mouse xenograft tumor model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Rat model of cholestasis induced by bile duct ligation ^[2]
Dosage:

150 mg/kg
Administration:

Oral gavage (p.o.) Once a day for 2 weeks
Result:

Reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in rats, and alleviates bile duct hyperplasia, parenchymal necrosis and fibrosis.
Increased total bile acid (TBA) levels in serum and bile and decreased total bile acid (TBA) levels in the liver.
Increased the expression of genes encoding bile acid transporters BSEP (Abcb11) and MRP2 (Abcc2) in liver tissue.
Decreased liver CD68 and NF-κB levels, serum and liver MDA levels, and significantly increased serum and liver superoxide dismutase activity.

Animal Model:

High-fat diet mice ^[3]
Dosage:

50 mg/kg
Administration:

i.g.; once a day for 8 weeks
Result:

Reduces hepatic DAG production and prevents PKCε ectopic translocation to the membrane, thereby inhibiting PKCε activation.
Increased the low levels of IRβ and PI3Kp85 and reversed the downregulation of IRS-2 and AKT phosphorylation levels.

Animal Model:

Female nude mice xenograft tumor model^[4]
Dosage:

500 和 1000 mg/kg
Administration:

p.o.; once a day for 45 days
Result:

The tumor growth inhibition rates were 22.1% and 67.6%, respectively.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 643-12-9
Appearance Solid
Molecular Weight 180.16
Formula C₆H₁₂O₆
Color White to off-white
SMILES

O[C@H]1[C@@H]([C@@H]([C@H]([C@@H]([C@H]1O)O)O)O)O
Structure Classification
- Others
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

H₂O : 75 mg/mL (416.30 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.5506 mL

27.7531 mL

55.5062 mL

5 mM

1.1101 mL

5.5506 mL

11.1012 mL

10 mM

0.5551 mL

2.7753 mL

5.5506 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (555.06 mM); Clear solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ostlund RE Jr, et al. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol. J Biol Chem. 1996 Apr 26;271(17):10073-8. [Content Brief]

[2]. Zhao SS, et al. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acidsecretion and attenuating oxidative stress. Acta Pharmacol Sin. 2018 Feb;39(2):213-221. [Content Brief]

[3]. Cheng F, et al. chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance viaPKCε-PI3K/AKT Pathway. J Agric Food Chem. 2019 May 29;67(21):5957-5967. [Content Brief]

[4]. Kim Y, et al. Inhibitory effect of D-chiro-inositol on both growth and recurrence of breast tumor from MDA-MB-231 cancer cells[J]. Natural Product Sciences, 2017, 23(1): 35-39.

[5]. Gambioli R, et al. New insights into the activities of D-chiro-inositol: a narrative review[J]. Biomedicines, 2021, 9(10): 1378. [Content Brief]

[6]. Iuorno M J, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome[J]. Endocrine Practice, 2002, 8(6): 417-423. [Content Brief]

[7]. Pintaudi B, et al. The effectiveness of Myo‐inositol and D‐chiro inositol treatment in type 2 diabetes[J]. International journal of endocrinology, 2016, 2016(1): 9132052. [Content Brief]

[8]. Larner J, et al. D‐chiro‐inositol–its functional role in insulin action and its deficit in insulin resistance[J]. Journal of Diabetes Research, 2002, 3(1): 47-60. [Content Brief]

[9]. Fortis-Barrera Á, et al. C ucurbita ficifolia Bouché (Cucurbitaceae) and D-chiro-inositol modulate the redox state and inflammation in 3T3-L1 adipocytes[J]. Journal of Pharmacy and Pharmacology, 2013, 65(10): 1563-1576. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.5506 mL	27.7531 mL	55.5062 mL	138.7655 mL
	5 mM	1.1101 mL	5.5506 mL	11.1012 mL	27.7531 mL
	10 mM	0.5551 mL	2.7753 mL	5.5506 mL	13.8766 mL
	15 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	20 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9383 mL
	25 mM	0.2220 mL	1.1101 mL	2.2202 mL	5.5506 mL
	30 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	40 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4691 mL
	50 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	60 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	80 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	100 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

D-chiro-Inositol

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Animal-Sourced Natural Product Library

Cytokine Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Carbohydrate Metabolite Compound Library

All Endogenous Metabolite Isoforms

All NF-κB Isoforms

All TNF Receptor Isoforms

All FOXO Isoforms

Biological Activity